OptiNose, Inc. (OPTN)
USD 9.1
(0.33%)
USD 9.1
(0.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 58.06 Million USD | 57.24% |
| 2022 | 36.92 Million USD | 82.81% |
| 2021 | 20.2 Million USD | 206.57% |
| 2020 | -18.95 Million USD | 73.9% |
| 2019 | -72.61 Million USD | 43.49% |
| 2018 | -128.49 Million USD | 21.17% |
| 2017 | -162.99 Million USD | -656.65% |
| 2016 | -21.54 Million USD | -2900.14% |
| 2015 | -718 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 34.8 Million USD | -56.35% |
| 2024 Q1 | 79.73 Million USD | 37.32% |
| 2023 Q4 | 58.06 Million USD | -9.41% |
| 2023 Q3 | 64.09 Million USD | 7.76% |
| 2023 Q1 | 46.69 Million USD | 26.45% |
| 2023 Q2 | 59.48 Million USD | 27.39% |
| 2023 FY | 58.06 Million USD | 57.24% |
| 2022 Q3 | 69.27 Million USD | 34.32% |
| 2022 FY | 36.92 Million USD | 82.81% |
| 2022 Q1 | 37.9 Million USD | 87.63% |
| 2022 Q2 | 51.57 Million USD | 36.08% |
| 2022 Q4 | 36.92 Million USD | -46.69% |
| 2021 Q3 | 44.42 Million USD | 29.7% |
| 2021 Q4 | 20.2 Million USD | -54.53% |
| 2021 FY | 20.2 Million USD | 206.57% |
| 2021 Q1 | 11.73 Million USD | 161.89% |
| 2021 Q2 | 34.25 Million USD | 191.97% |
| 2020 FY | -18.95 Million USD | 73.9% |
| 2020 Q1 | -42.47 Million USD | 41.51% |
| 2020 Q4 | -18.95 Million USD | 47.67% |
| 2020 Q3 | -36.21 Million USD | -89.99% |
| 2020 Q2 | -19.06 Million USD | 55.12% |
| 2019 FY | -72.61 Million USD | 43.49% |
| 2019 Q1 | -97.12 Million USD | 24.41% |
| 2019 Q2 | -69.64 Million USD | 28.29% |
| 2019 Q3 | -49.83 Million USD | 28.45% |
| 2019 Q4 | -72.61 Million USD | -45.71% |
| 2018 Q4 | -128.49 Million USD | 13.87% |
| 2018 FY | -128.49 Million USD | 21.17% |
| 2018 Q1 | -137.8 Million USD | 15.45% |
| 2018 Q2 | -172.85 Million USD | -25.43% |
| 2018 Q3 | -149.17 Million USD | 13.7% |
| 2017 Q2 | -58.88 Million USD | 7.97% |
| 2017 Q1 | -63.98 Million USD | -197.04% |
| 2017 FY | -162.99 Million USD | -656.65% |
| 2017 Q4 | -162.99 Million USD | -229.87% |
| 2017 Q3 | -49.41 Million USD | 16.09% |
| 2016 FY | -21.54 Million USD | -2900.14% |
| 2016 Q4 | -21.54 Million USD | 0.0% |
| 2015 FY | -718 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 86.662% |
| Embecta Corp. | 1.31 Billion USD | 95.574% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 38.364% |
| Dynavax Technologies Corporation | 106.63 Million USD | 45.548% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 87.341% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 86.582% |
| PainReform Ltd. | -7.95 Million USD | 830.377% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 22.528% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 471.387% |
| SCYNEXIS, Inc. | -19.35 Million USD | 400.078% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 715.765% |
| Cosmos Health Inc. | 8.59 Million USD | -575.901% |
| Journey Medical Corporation | -9.7 Million USD | 698.053% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 471.387% |
| Safety Shot Inc | -2.28 Million USD | 2641.833% |
| Alpha Teknova, Inc. | 1.97 Million USD | -2841.489% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 144.382% |
| Bright Green Corporation | 1.84 Million USD | -3052.753% |
| Procaps Group, S.A. | 242.93 Million USD | 76.098% |
| Theratechnologies Inc. | 24.87 Million USD | -133.465% |
| Harrow Health, Inc. | 116.41 Million USD | 50.123% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 2404.167% |
| Biofrontera Inc. | 4.05 Million USD | -1331.583% |
| DURECT Corporation | -7.65 Million USD | 858.623% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 273.189% |
| Cronos Group Inc. | -663.32 Million USD | 108.754% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 90.686% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 498.47% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 1219.642% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -286.765% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 1013.023% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -54237.959% |
| Radius Health, Inc. | 359.28 Million USD | 83.839% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -29343.382% |
| ProPhase Labs, Inc. | 19.23 Million USD | -201.934% |
| Phibro Animal Health Corporation | 454.84 Million USD | 87.234% |
| Procaps Group S.A. | 242.93 Million USD | 76.098% |
| Alvotech | 1.06 Billion USD | 94.544% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -1478.711% |
| Viatris Inc. | 17.13 Billion USD | 99.661% |
| Rockwell Medical, Inc. | 4.45 Million USD | -1203.075% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 1290.588% |
| SIGA Technologies, Inc. | -148.68 Million USD | 139.053% |
| Tilray Brands, Inc. | 158.97 Million USD | 63.476% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 52.366% |
| Shineco, Inc. | 29.29 Million USD | -98.24% |
| PetIQ, Inc. | 351.93 Million USD | 83.501% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 2101.256% |
| Incannex Healthcare Limited | -5.48 Million USD | 1158.614% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 67.25% |
| Alimera Sciences, Inc. | 55.3 Million USD | -4.983% |
| Silver Spike Investment Corp. | -32.61 Million USD | 278.05% |
| Assertio Holdings, Inc. | -32.52 Million USD | 278.502% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 4000.325% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 1247.443% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 1306.17% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 806.948% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -1276.927% |
| Hempacco Co., Inc. | 13.61 Million USD | -326.488% |
| Talphera, Inc. | -5.72 Million USD | 1114.945% |
| Alvotech | 1.06 Billion USD | 94.544% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -712.666% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 160.04% |
| Currenc Group, Inc. | -16.57 Million USD | 450.356% |
| Kamada Ltd. | -46.43 Million USD | 225.055% |
| Indivior PLC | -33.95 Million USD | 271.021% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -22183.497% |
| Flora Growth Corp. | -713 Thousand USD | 8243.759% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 806.948% |
| Evolus, Inc. | 63.7 Million USD | 8.858% |
| HUTCHMED (China) Limited | -197.45 Million USD | 129.406% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 87.881% |
| Akanda Corp. | 3.9 Million USD | -1386.972% |